PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
NEW YORK, May 15, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of investors who purchased Lion Biotechnologies, Inc. ("Lion Biotechnologies") (NASDAQ:LBIO) securities between November 14, 2013 and April 10, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra-sa/lion-biotechnologies-inc?wire=3. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (1) through its former CEO Manish Singh, Lion was engaged in a scheme to mislead investors by commissioning over 10 internet publications and 20 widely distributed emails promoting the Company to potential investors that purported to be independent from the company when, in truth, they were paid promotions; (2) Singh engaged a notorious stock promotion firm to pay writers to publish articles about Lion on investment websites, as well as to coordinate the distribution of articles to thousands of electronic mailboxes; (3) Singh actively participated in the promotional work for the Company and understood that the promotion firm was using writers who would not disclose that Lion was indirectly compensating them for their publications; and (4) consequently, defendants’ public statements were materially false and misleading at all relevant times.
If you suffered a loss in Lion Biotechnologies you have until June 13, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-sa/lion-biotechnologies-inc?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
